- Retrospective comparative observational study of 196 patients (98 per group) undergoing high-definition lipoabdominoplasty under general anesthesia.
- Group A received semaglutide or tirzepatide, while Group B received no GLP-1 receptor agonist therapy.
- No statistically significant between-group differences were found in intraoperative adverse events, recovery times, nausea and vomiting, pain scores, or early complications; the abstract gives no effect sizes or p values.
- The authors state these null findings do not show equivalence, since the study was not designed for non-inferiority testing and may be underpowered for rare events.
Latest papers
Research from anesthesiology, pain and critical care journals, sourced from PubMed.
Sorted by publication date, not import date. Recent filters exclude papers with only a publication year; find those under All years.
AI-generated abstract summaries can contain errors. Verify findings against the original paper before applying them to patient care.
Last successful paper check: 16 Nov 2026 17:18 UTC.
0 newly discovered papers saved; these are not necessarily published today.
2 papers awaiting AI summaries. Summary processing had an error; paper-fetch status is separate.
Background checks run while the server is active. This does not guarantee a daily run if hosting sleeps.
2 papers awaiting AI summaries. Summary processing had an error; paper-fetch status is separate.
Background checks run while the server is active. This does not guarantee a daily run if hosting sleeps.
- Retrospective hospital database study of adults meeting Sepsis-3 criteria, with 31,109 patients after excluding positive nonviral cultures and 1034 (3.3%) classified as viral sepsis.
- Compared viral sepsis with nonviral sepsis, and examined associations with mortality including mechanical ventilation, SOFA score, lactate, and antiviral receipt.
- Viral sepsis had 15% 90-day mortality versus 20% for nonviral sepsis; after adjustment, mechanical ventilation (OR 3.142, 95% CI 1.692-5.836), SOFA score (OR 1.159), and lactate (OR 1.204) were associated with mortality.
- Antiviral medication receipt was not associated with better survival (OR 1.160, 95% CI 0.142-9.449, P = .875), per the authors.
- Randomized, blinded crossover OSCE study at two academic centers, analyzing 79 PGY 2–4 anesthesiology residents across two clinically ambiguous simulated cases.
- Residents interacted with a standardized surgeon actor who was either civil or uncivil, and blinded attendings judged whether they proceeded or postponed surgery.
- Uncivil encounters made residents more likely to proceed with surgery (OR 2.25; 95% CI, 1.07-4.74; P = .03).
- Situational awareness, communication, and decision-making scores did not differ significantly between civil and uncivil encounters.
- Multicenter retrospective cohort of 18,835 pediatric airway encounters from 12 Japanese tertiary hospitals, with weight classified by WHO weight-for-age standard deviations.
- Exposure was weight category (obese, overweight, normal, or underweight) during the initial induction of general anesthesia.
- Obese (aOR 2.12, 95% CI 1.17-3.84) and underweight (aOR 1.31, 95% CI 1.05-1.64) status were associated with desaturation ≥10%; airway-related adverse events showed no association.
- Underweight status was also linked to lower first-attempt intubation success (aOR 0.69, 95% CI 0.60-0.79), which the authors suggest may mark high-risk patients.
AI summary not available. Read the source abstract on PubMed.
AI summary not available. Read the source abstract on PubMed.
- This meta-research analysis of 20 randomized HPI trials (2,342 patients) included 18 that reported both hypotension and treatment outcomes.
- Trials were grouped by whether HPI guidance significantly reduced hypotension and whether the HPI group received significantly more fluids, vasopressors, or inotropes.
- Among 13 trials with reduced hypotension, 9 (69%) showed greater treatment intensity, versus none of 5 trials without hypotension reduction (Fisher's exact p = 0.029).
- Time-weighted average differences in MAP below 65 mmHg correlated with treatment intensity categories (p < 0.001), and the authors conclude that reduced hypotension often came with more intensive treatment.
- Prospective single-institution cohort of 67 adolescents aged 10-18 yr, divided into a GLP1-RA group (n=20), an at-risk group not on GLP1-RAs (n=27), and healthy controls (n=20).
- All patients followed standard fasting of 8 h for solids and 1 h for clear liquids, and gastric contents were assessed by gastric ultrasound.
- Solids were present in 16/20 (80%) of the GLP1-RA group, versus 17/27 (63%) of the at-risk group and 1/20 (5%) of controls (unadjusted P<0.001; adjusted P<0.02).
- The authors conclude that most adolescents on GLP1-RAs still had solids on ultrasound despite median fasting over 12 h.
AI summary not available. Read the source abstract on PubMed.
AI summary not available. Read the source abstract on PubMed.
- Retrospective single-center cohort of 22 patients (16 cervical, 6 thoracic) who had SPECT/CT, dual medial branch blocks, and RFA between January 2023 and May 2025.
- Compared outcomes across SPECT/CT-RFA concordance subgroups; imaging was at physician discretion, so there was no non-SPECT/CT control arm.
- At first follow-up, 16/18 (89%) met the NRS MCID and 7/13 (54%) met the MODI MCID; concordance comparisons were underpowered, with wide confidence intervals.
- Authors report clinically meaningful pain reduction across all concordance categories and suggest SPECT/CT may complement planning, pending larger prospective studies.
- Retrospective chart review of 105 cervical transforaminal injections or selective nerve root blocks in 95 patients at one tertiary academic center.
- Antithrombotic therapy was continued for 25 procedures and interrupted for 80, and complications were compared between groups over 0 to 30 days.
- No hemorrhagic complications occurred in either group; ischemic events were 1/25 (4.0%) with continuation and 2/80 (2.5%) with interruption, p = 0.562.
- The authors describe the findings as mainly descriptive because of the small sample and few events, not definitive evidence of procedural safety or comparative ischemic risk.
- This narrative article describes Medicare's TEAM bundled-payment model and its implications for anesthesiology practice; it reports no original data or sample.
- TEAM replaces fee-for-service payment for discrete activities with episode-level risk sharing, and anesthesia reimbursement is included within the bundle.
- The authors argue that episode-based payment highlights anesthesiology work that fee-for-service has undervalued, such as complication prevention and perioperative optimization.
- They conclude that anesthesiologists need to define, measure, and report outcomes reflecting their effect on recovery and resource use to show their value under these models.
- A prospective multicentre cohort at seven Dutch hospitals enrolled 103 frail patients (mean age 87) who chose non-operative management of hip fracture.
- All patients received an ultrasound-guided pericapsular nerve group block with phenol 6% (mean 10 ml), with a second needle needed in 14%; there was no comparator group.
- At 1 week, 34/36 (94%) reported acceptable pain at rest, and 24/53 (45%) could transfer from bed to chair.
- Three-month mortality was 72/91 (79%), with median survival of 9 days; the authors describe the block as an effective add-on analgesic.
- This overview reviews health economic principles and published full and partial economic evaluations of intrathecal drug delivery (ITDD) systems across cancer pain, chronic non-cancer pain, and spasticity.
- ITDD is compared with conventional management strategies, and the analyses span varying perspectives and healthcare settings.
- Most analyses suggest ITDD is cost-effective, particularly for cancer-related pain and spasticity, though the authors caution that findings rest on heterogeneous methods and often small or uncontrolled effectiveness data.
- Evidence for chronic non-cancer pain is sparse and inconsistent, and the authors call for comparative effectiveness research and long-term economic modeling.
- This case report describes one patient with prior lumbar spine surgery and refractory low back pain who had two intrathecal pump explants for suspected infection.
- The patient was ultimately diagnosed with type IV titanium hypersensitivity, and the pump was reimplanted after being encased in an expanded polytetrafluoroethylene (ePTFE) fabric pouch.
- The reimplanted intrathecal drug delivery system was reported as successful, with no rejection described.
- The authors conclude that device-component hypersensitivity should be considered in recurrent or unexplained pump site complications, and that an ePTFE pouch may allow reimplantation.
- This narrative review draws on PubMed, Google Scholar, reference lists, and intrathecal pump device manuals to cover perioperative, obstetric, and ICU care of patients with implanted intrathecal drug delivery systems.
- It is organized into five sections: intrathecal pharmacology, implantation considerations, perioperative care, neuraxial anesthesia, and device-related safety concerns.
- Where evidence is limited, the authors supplement the literature with expert opinion, so some recommendations rest on consensus rather than data.
- The authors highlight intrathecal medications, their behavior under MRI, and precautions before any neuraxial access in these patients.
- A retrospective single-center study of 53 patients with refractory cancer pain on intrathecal infusion systems, where the sequential flex mode was used after continuous mode failed.
- The sequential flex mode uses a basal flow with large boluses and was compared with the prior continuous flow rate mode in the same patients.
- 71.7% ± 6.43% of patients achieved at least 30% NRS reduction, and median NRS fell from 6.4 (SD 2.0) to 3.3 (SD 2.2), p<0.0001.
- The authors conclude the flex mode may improve pain relief and limit dose escalation, with adverse effects in 20.3% of switches, mostly non-serious increased anxiety.
- This is a historical commentary, not a primary study, tracing neuraxial therapeutics for pain over roughly the past 50 years.
- It covers the advances leading to current neuraxially targeted therapies and considers where this line of development may lead.
- The abstract reports no quantitative results, sample sizes, or comparative outcomes, so it offers a narrative overview rather than evidence of effect.
- This practical guide synthesizes evidence, consensus recommendations, and international clinical experience on intrathecal drug delivery for refractory pain.
- It covers preimplant evaluation, trialing, pump and catheter selection, perioperative care, early troubleshooting, long-term maintenance, and complication surveillance.
- It reviews intrathecal opioids, local anesthetics, ziconotide, clonidine, and baclofen, with attention to indication-specific dosing and safety, but reports no pooled quantitative results.
- It frames outcomes beyond pain intensity, including function, quality of life, and reduced systemic medication use, and addresses cancer and non-cancer populations separately.
- Retrospective single-center study of 215 patients with chronic non-cancer pain who received intrathecal drug delivery devices between 2009 and 2022, most with PSPS2 (184 patients).
- The exposure was intrathecal drug delivery, and explant reasons were compared with spinal cord stimulation explant rates from a similar patient population.
- The explant rate was 26.1%, with device-related infection the leading cause in 9.3% of patients (5.9% of device surgeries) and loss of analgesic efficacy in 5.6%.
- Infections occurred earlier after implant than other complications, and no demographic or comorbidity factors correlated with explant, per the authors.
- Single-center retrospective chart review of 441 cancer patients with intrathecal pumps, of whom 117 had two chest CTs at least 30 days apart.
- No comparator; catheter migration was defined as movement of one or more vertebral levels between the two imaging studies.
- Migration occurred in 15.4% (18 of 117), all limited to a single level; revision-requiring migration occurred in 2 of 441 (0.45%).
- The authors conclude minor migration is common but clinically significant migration is rare with their anchoring and closure techniques, and no demographic factors were associated.
- Retrospective case series of five patients with chronic pain and regionally localized pain who had implanted intrathecal devices and received bupivacaine monotherapy.
- Device duration ranged from over 2 to over 12 years, and two patients had moved from an opioid-bupivacaine combination to bupivacaine alone.
- All five patients reported at least 50% pain relief and stopped systemic opioids.
- The authors suggest monotherapy may be effective for localized pain but state that more studies are needed to establish its safety and efficacy.
- A single-center retrospective study of 31 patients, with 162 serial blood samples drawn before pump refills during intrathecal bupivacaine for cancer pain.
- Serum bupivacaine concentration was examined against daily dose and infusion flow rate, with body mass index also assessed as a factor.
- Mean serum concentration was 167.7 µg/L (SD 266.2) at a mean daily dose of 39.5 mg/day (SD 31.4), and concentration rose with dose.
- Higher flow rates stayed independently associated with concentration after adjusting for dose, and the authors conclude exposure is well below the toxicity threshold.
- This narrative review searched five databases and screened studies with three reviewers, then synthesized them descriptively due to heterogeneity.
- It examines intrathecal drug delivery systems for less common refractory pain, including spinal cord injury pain, transverse myelitis, diabetic neuropathy, postherpetic neuralgia and craniofacial pain.
- The authors found the evidence rests mainly on observational studies and small trials, with possible meaningful relief in selected patients but variable magnitude and durability of response.
- They conclude the evidence is limited, that selective clinical use may contribute to this gap, and that future research is needed to define its role.
- Retrospective single-center cohort of 435 patients with cancer pain treated with intrathecal drug delivery from 2013 to 2023; 222 met inclusion criteria.
- Longitudinal Brief Pain Inventory and Condensed Memorial Symptom Assessment Scale scores were compared before and after implantation, with no concurrent comparator group.
- Over the first 90 days, pain severity, pain interference, and physical symptom scores each declined per day (BPI-SEV -0.014, 95% CI -0.020 to -0.009; BPI-INT -0.020; CMSAS-PHYS -0.004), and 91% stopped systemic opioids.
- Scores worsened before implantation and improved afterward, and the authors report benefits sustained up to one year.
- Systematic review and meta-analysis of 39 studies (n=2652) in adults with chronic non-cancer pain treated with intrathecal drug delivery.
- Twenty single-arm comparisons contributed to the pain-intensity meta-analysis at 12 months, so there was no controlled comparator.
- Pooled pain reduction from baseline was 2.64 (95% CI 2.19 to 3.08), with a 75% probability of exceeding the 2-unit MCID (95% CI 68% to 83%).
- All studies reported functional and HRQoL improvements, but adverse event reporting was inconsistent and certainty of evidence was low.
AI summary not available. Read the source abstract on PubMed.
AI summary not available. Read the source abstract on PubMed.
- In 42 healthy volunteers receiving fluctuating noxious heat, researchers trained deep learning models to detect pain decreases from brief physiological signal windows.
- The models combined electrodermal activity, heart rate, pupil diameter, and other signals, with a transformer architecture performing best on a held-out test set of 9 participants.
- The best combined model reached AUROC 0.854 and accuracy 76.8%; continuous detection had median latency 5.75 seconds and 70.4% sensitivity.
- Electrodermal activity was the most informative single predictor, and the authors suggest electrodermal activity and heart rate suit practical deployment while EEG and facial expressions need personalized models.
- Preclinical mouse study of male and female mice with apical periodontitis induced by pulp exposure, compared with sham surgery, assessing mechanical hypersensitivity with von Frey filaments at day 21.
- Single oral CBD dose versus vehicle, with intrathecal, intracisternal, and intraoral CBD routes and TRPV1 antagonist AMG 517 pretreatment to probe site of action and mechanism.
- Oral CBD significantly reduced mechanical hypersensitivity at 45 and 120 minutes, with a greater effect in males than females; no numerical effect sizes or p values are given in the abstract.
- Authors conclude oral CBD is an effective analgesic for apical periodontitis-induced hypersensitivity acting centrally and involving TRPV1, based on this model.
- Two experiments (Study A n=74, Study B n=60; 134 participants total) tested unfamiliar music during thermal pain stimulation, with excerpts selected using the Arousal, Valence, Depth model.
- Musical excerpts were chosen to be high in arousal or depth, and the analysis examined how participants' pleasantness ratings related to their pain responses.
- In Study A, high-arousal music increased pain unpleasantness and high-depth music provided relief, and these effects were completely mediated by pleasantness ratings.
- Study B replicated the benefit of musical depth and found participants' perceptions aligned with AVD dimension loadings; trait systemizing moderated depth analgesia in one study.
- Retrospective TriNetX cohort of 5,876 adults with type II diabetes undergoing rotator cuff repair from 2018 to 2024, including 233 preoperative GLP-1 agonist users.
- Compared preoperative GLP-1 agonist exposure with non-exposure for 90-day medical, surgical, and healthcare utilization outcomes, using unadjusted and inverse propensity score-weighted logistic regression.
- Unadjusted analyses showed higher odds of respiratory complications (OR 1.97, 95% CI 1.32-2.86), UTI (OR 3.85), and stiffness (OR 2.20); after weighting, no significant differences.
- The authors found no independent association between GLP-1 use and complication risk and suggest perioperative continuation may be safe, while calling for prospective studies.
- Retrospective TriNetX cohort of adults undergoing ACDF; the primary high-dose versus standard-dose comparison included 921 propensity-matched patients per arm.
- Exposure was the GLP-1 receptor agonist prescription strength recorded from 1 year to 1 week before surgery, comparing high-dose with standard-dose use.
- Ninety-day readmission was 11.4% versus 10.0% (p=.327), and opioid exposure was 85.2% versus 83.1% (p=.202), with no significant differences in complications or fusion outcomes.
- Both standard-dose and high-dose users had lower pseudarthrosis rates than nonusers, but higher dose added no further long-term benefit, and the authors conclude high-dose therapy does not add perioperative or fusion risk.
- This qualitative study followed ten adolescents aged 12-15 with longstanding non-traumatic knee pain through two online semi-structured interviews.
- Interviews occurred 1-3 days and then 11-17 days after a clinical consultation, and were analyzed with reflexive thematic analysis and matrix analysis.
- Six key areas emerged over time, including limited recall of medical information, seeking proof, and a rigid activity-versus-rest dichotomy.
- The authors conclude that adolescents' perceptions are dynamic and that communication and self-management support should be personalized.
- In a cross-sectional study of about 950,000 Million Veteran Program participants with at least two visits, two EHR code-based phenotyping strategies were compared for 17 pain, internalizing, and opioid use conditions.
- The Multiple Code strategy, requiring one inpatient or two outpatient codes, was compared with the Any Code strategy requiring a single code.
- Multiple Code excluded 33.5% of Any Code cases on average, and the observed change in correlations (mean |Δr|=0.014) was smaller than in all 1000 random-thinning replicates.
- Both strategies supported a correlated four-factor model (CFI=0.987), and the authors conclude that the stricter definition changes case mix and prevalence but preserves the overall relationships among conditions.
- Systematic review and meta-analysis of 27 randomized controlled trials including 3041 patients undergoing surgery, searched from inception to December 2025.
- Perioperative vitamin C was compared with control; the review pooled effects on pain, opioid use, rescue analgesia, nausea and vomiting, and CRPS-1.
- Vitamin C reduced pain at 24 h (SMD -0.69, 95% CI -0.98 to -0.40) and 24-h morphine use (MD -4.25 mg, 95% CI -6.14 to -2.35), with rescue analgesia also reduced (RR 0.63, 95% CI 0.47 to 0.84).
- Authors say evidence may support reduced acute pain and opioid use with a favorable safety profile, but heterogeneity and publication bias limit it, and routine recommendation is not yet supported; CRPS-1 risk was lower in high-risk orthopedic patients (RR 0.36, 95% CI 0.23 to 0.58).
- Retrospective multicenter cohort of 269 critically ill children with acute cardiorespiratory failure and hyperglycemia, treated in PICUs from 2012 to 2016.
- A three-marker classifier (IL-6, IL-8, sTNFR-1) built on conventional multiplex data was applied to rapid immunoassay measurements, and a de novo rapid-assay classifier was also derived.
- The de novo classifier had an AUROC of 0.90 (95% CI, 0.86-0.95), matched latent class classifications in 241 of 269 cases (89.6%), and showed mortality of 33.3% versus 11.8% (p = 0.009).
- Rapid-assay subphenotypes differed in response to intensive insulin management (interaction p = 0.024), and the authors suggest this approach could inform future subphenotype-based precision trials.
- Double-blind randomized placebo-controlled trial in 120 mechanically ventilated adults on opioid infusion at two Melbourne ICUs, excluding cardiac surgical patients.
- Patients received low-dose ketamine infusion (0.15 mg/kg/hr) or placebo during mechanical ventilation.
- Median hourly opioid dose was 64 µg/hr with ketamine versus 77 µg/hr with placebo (median difference -13.0, 95% credible interval -26.6 to 2.4; probability of benefit 95.1%).
- Authors concluded low-dose ketamine appeared safe and reduced opioid requirements, while noting that delirium and most other secondary outcomes did not differ and larger trials are needed.
- A retrospective, nationwide registry cohort in Sweden included 92,428 COVID-19 and 21,355 influenza hospitalizations, with COVID-19 split into five pandemic-period groups.
- Cox regression, adjusted for age, sex, socioeconomic factors, comorbidities, and SARS-CoV-2 vaccination, identified predictors of ICU admission and in-hospital mortality, and influenza served as the comparator.
- Hospitalization rates were lowest in the delta period and ICU admission rates were lowest in the Omicron period, and Omicron patients most closely resembled influenza patients in demographics, stay, ICU use, and mortality.
- Advanced age was the strongest predictor of severe illness for both infections, and lack of vaccination was additionally associated with severe COVID-19.